Filing Details

Accession Number:
0000899243-18-017779
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-06-22 18:56:18
Reporting Period:
2018-06-22
Accepted Time:
2018-06-22 18:56:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1731831 Eidos Therapeutics Inc. EIDX Pharmaceutical Preparations (2834) 463733671
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1742485 Neil Kumar C/O Eidos Therapeutics, Inc.
101 Montgomery Street, Suite 2550
San Francisco CA 94104
Chief Executive Officer Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-06-22 18,826,417 $0.00 18,826,417 No 4 C Indirect See footnote
Common Stock Disposition 2018-06-22 211,762 $17.00 18,614,655 No 4 F Indirect See footnote
Common Stock Acquisiton 2018-06-22 1,000,000 $17.00 19,614,655 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 F Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Series B Preferred Stock Warrants Disposition 2018-06-22 332,262 $0.00 332,262 $10.83
Common Stock Series B Convertible Preferred Stock Acquisiton 2018-06-22 332,262 $0.00 397,385 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2018-06-22 2,909,029 $0.00 3,479,198 $0.00
Common Stock Series Seed Preferred Stock Disposition 2018-06-22 12,832,123 $0.00 15,347,219 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 X Indirect
2,909,029 No 4 X Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Immediately prior to completion of the Issuer's initial public offering, the warrants were automatically exercised for shares of Series B Preferred Stock and such shares acquired were automatically converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock.
  2. The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.
  3. Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.